New Research: Venous thromboembolism (VTE).
Datamonitor Healthcare has produced an in-depth review of the key marketed drugs and pipeline products including pipeline trends and future treatment paradigms, for the venous thromboembolism (VTE) market within the US, Japan, and five major EU markets*.
Today we are offering you a sample extract of our analysis of the VTE market to provide you with the valuable insight you need, to stay one step ahead of your competitors.
Gain access to our sample extract, and determine your company’s competitiveness in the market place. The complete report reviews:
- Competitive landscape: Detailed analysis of key marketed drugs
- Market share: Explore how the approval of Pradaxa’s antidote will affect sales of novel oral antigualants (NOACs) Eliquis (apixaban; Bristol-Myers Squibb/Pfizer) and Xarelto (rivaroxaban; Bayer/Johnson & Johnson)
- Driving forces: Examine how novel oral anticoagulant (NOAC) such as Betrixaban (Portola Pharmaceuticals) will become the standard of care for acutely ill patients when it gains approval in the VTE market
Explore our forecast on VTE by downloading your exclusive extract from this market leading report >>
If you’re already a subscriber to Datamonitor Healthcare, click here to access the full report.